The glucagon-like peptide-1 (GLP-1) system was recently established as a target for type 2 diabetes (T2D) and obesity treatment1–3, as it improves blood glucose regulation, reduces food intake, and helps to manage body weight4, 5. Here, GCG is linked to obesity disorder.